PRMT2

Across TCGA pan-cancer cohorts, PRMT2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated PRMT2 data layer compared with 24 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher PRMT2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated PRMT2 expression acts as an unfavorable survival marker, although some lineages such as LUAD and PDAC show a favorable association.

LUAD, PDAC, and HNSC are the cancer types where PRMT2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Tertile	II,III,IV	0.696	0.283	.004	13	view →
PDAC	OS	Median	All	0.607	0.337	.003	12	view →
HNSC	OS	Tertile	All	0.951	0.719	.018	6	view →
LSCC	OS	Tertile	All	1.000	0.911	.035	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

PRMT2–LUAD (DFS)

Open the LUAD breakdown →